Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim) was approved July 20 by the Food and Drug Administration, according to a statement provided by the agency.is the second biosimilar to Neupogen to be approved in the United States.
Nivestym is approved for the same indications as Neupogen and can be prescribed for:
- Patients with cancer receiving myelosuppressive chemotherapy.
- Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy.
- Patients with cancer undergoing bone marrow transplantation.
- Patients undergoing autologous peripheral blood progenitor cell collection and therapy.
- Patients with severe chronic neutropenia.
Prescribing information is
U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi), Pfizer press release
This Week's Must Reads
Novel agents emerge for hemophilia, Shapiro AD, et al. J Thromb Haemost. 2018 Sep 28
Bleeding risk with acute myocardial infarction, Dodson JA et al. JACC Cardiovasc Interv. 2018 Nov 26;11:2287-96
Identifying thrombosis risk in ITP patients, Balitsky AK et al. Blood. 2018 Nov 8. doi: 10.1182/blood-2018-08-868406
Preop blood management lessons, Cahill CM et al. AABB 2018, Abstract PBM4-ST4-22
Treating osteoporosis caused by transfusion-dependent thalassemia , Terpos E et al. Blood Adv. 2018;2:2837-47
Must Reads in AML
Phase 2 results for combo therapy in relapsed AML, Daver N et al. Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774
Transcription factor networks in AML, Assi SA et al. Nat Genet. 2018 Nov 12. doi: 10.1038/s41588-018-0270-1
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.
T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51